Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B SMALL

Showing results (91-100 of 124) with videos related to

Pageof 13
Sort By:
HIV Medicine|July 16, 2015
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavirD A Wohl, L Bhatti, C B Small, et al.
Neurology|December 10, 2008
Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer diseaseR Duara, D A Loewenstein, E Potter, et al.
HIV Clinical Trials|January 19, 2016
Corrigendum. Hepatic Safety in Subjects With HIV-1 and Hepatitis C and/or B Virus: A Randomised, Double-Blind Study of Maraviroc vs Placebo in Combination With Antiretroviral AgentsJùrgen K Rockstroch, Vicente Soriano, Frank Plonski, et al.
American Journal of Veterinary Research|March 1, 1985
Dose-response evaluation of a genetically engineered foot-and-mouth disease virus polypeptide immunogen in cattleP D McKercher, D M Moore, D O Morgan, et al.
HIV Clinical Trials|April 30, 2015
Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agentsJuergen K Rockstroh, Vicente Soriano, Frank Plonski, et al.
Journal of Virology|June 1, 1985
Nucleotide and amino acid sequence coding for polypeptides of foot-and-mouth disease virus type A12B H Robertson, M J Grubman, G N Weddell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 6, 2019
Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant RecipientsWesley S Rogers, Lars F Westblade, Rosemary Soave, et al.
Journal of Clinical Pathology|April 29, 2004
In vivo and in vitro studies on Anaplasma phagocytophilum infection of the myeloid cells of a patient with chronic myelogenous leukaemia and human granulocytic ehrlichiosisM Bayard-Mc Neeley, A Bansal, I Chowdhury, et al.
NPJ Vaccines|December 20, 2024
Establishing an immune correlate of protection for Nipah virus in nonhuman primatesV H Leyva-Grado, D Promeneur, K N Agans, et al.
Open Forum Infectious Diseases|November 16, 2022
Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhu GM-CSF) as Adjuvant Therapy for Invasive Fungal DiseasesTempe K Chen, Jagmohan S Batra, David E Michalik, et al.
Pageof 13

Showing results (91-100 of 124) with videos related to

Sort By:
Pageof 13
HIV Medicine|July 16, 2015
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavirD A Wohl, L Bhatti, C B Small, et al.
Neurology|December 10, 2008
Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer diseaseR Duara, D A Loewenstein, E Potter, et al.
HIV Clinical Trials|January 19, 2016
Corrigendum. Hepatic Safety in Subjects With HIV-1 and Hepatitis C and/or B Virus: A Randomised, Double-Blind Study of Maraviroc vs Placebo in Combination With Antiretroviral AgentsJùrgen K Rockstroch, Vicente Soriano, Frank Plonski, et al.
American Journal of Veterinary Research|March 1, 1985
Dose-response evaluation of a genetically engineered foot-and-mouth disease virus polypeptide immunogen in cattleP D McKercher, D M Moore, D O Morgan, et al.
HIV Clinical Trials|April 30, 2015
Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agentsJuergen K Rockstroh, Vicente Soriano, Frank Plonski, et al.
Journal of Virology|June 1, 1985
Nucleotide and amino acid sequence coding for polypeptides of foot-and-mouth disease virus type A12B H Robertson, M J Grubman, G N Weddell, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 6, 2019
Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant RecipientsWesley S Rogers, Lars F Westblade, Rosemary Soave, et al.
Journal of Clinical Pathology|April 29, 2004
In vivo and in vitro studies on Anaplasma phagocytophilum infection of the myeloid cells of a patient with chronic myelogenous leukaemia and human granulocytic ehrlichiosisM Bayard-Mc Neeley, A Bansal, I Chowdhury, et al.
NPJ Vaccines|December 20, 2024
Establishing an immune correlate of protection for Nipah virus in nonhuman primatesV H Leyva-Grado, D Promeneur, K N Agans, et al.
Open Forum Infectious Diseases|November 16, 2022
Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhu GM-CSF) as Adjuvant Therapy for Invasive Fungal DiseasesTempe K Chen, Jagmohan S Batra, David E Michalik, et al.
Pageof 13